Anbio Biotechnology (NNNN) Liabilities and Shareholders Equity (2023 - 2025)

Anbio Biotechnology's quarterly Liabilities and Shareholders Equity came in at $30.2 million in Q4 2025, up 59.83% year-on-year from $18.9 million in Q4 2024, and up 59.83% quarter-over-quarter from $18.9 million in Q4 2024.

Anbio Biotechnology has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $30.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn 20.11 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn 50.83 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 8.78 Bn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn 4.11 Bn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn 14.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 12.42 Bn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 6.31 Bn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn 19.85 Bn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 5.10 Bn
10 Anbio Biotechnology 1.32 Bn 1.31 Bn - 30.24 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 30.24 Mn
Jun 30, 2025 27,680.59 Bn
Dec 31, 2024 18.92 Mn
Dec 31, 2023 15.81 Mn